[go: up one dir, main page]

AR040721A1 - Metodos y formas de dosificacion para l aliberacion controlada de paliperidona - Google Patents

Metodos y formas de dosificacion para l aliberacion controlada de paliperidona

Info

Publication number
AR040721A1
AR040721A1 AR20030102717A ARP030102717A AR040721A1 AR 040721 A1 AR040721 A1 AR 040721A1 AR 20030102717 A AR20030102717 A AR 20030102717A AR P030102717 A ARP030102717 A AR P030102717A AR 040721 A1 AR040721 A1 AR 040721A1
Authority
AR
Argentina
Prior art keywords
paliperidone
methods
plasma
dosage
takes place
Prior art date
Application number
AR20030102717A
Other languages
English (en)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31191280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR040721(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR040721A1 publication Critical patent/AR040721A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formas de dosificación y los métodos para suministrar una velocidad de liberación de paliperidona sustancialmente ascendente. Las formas de dosificación de liberación sostenida proveen concentraciones promedio de paliperidona en plasma en el estado estacionario terapéuticamente efectivas cuando se administran una vez al día. Este régimen de dosificación de una vez al día da como resultado la existencia de sólo una concentración plasmática pico de paliperidona en cada período de 24 horas. Además, la concentración pico de paliperidona en plasma tiene lugar a un tiempo posterior después de la administración de la dosis, y muestra una magnitud inferior a la concnetración pico de paliperidona en plasma que tiene lugar luego de la administración de paliperidona en una forma de dosificación de liberación inmediata.
AR20030102717A 2002-07-29 2003-07-29 Metodos y formas de dosificacion para l aliberacion controlada de paliperidona AR040721A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39959002P 2002-07-29 2002-07-29
US40600502P 2002-08-26 2002-08-26

Publications (1)

Publication Number Publication Date
AR040721A1 true AR040721A1 (es) 2005-04-20

Family

ID=31191280

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102717A AR040721A1 (es) 2002-07-29 2003-07-29 Metodos y formas de dosificacion para l aliberacion controlada de paliperidona

Country Status (28)

Country Link
US (1) US20040092534A1 (es)
EP (1) EP1539115B1 (es)
JP (1) JP4500679B2 (es)
KR (1) KR100699516B1 (es)
CN (1) CN1684670A (es)
AR (1) AR040721A1 (es)
AT (1) ATE373472T1 (es)
AU (1) AU2003256844A1 (es)
BR (1) BR0313139A (es)
CA (1) CA2494234C (es)
CO (1) CO5580742A2 (es)
CY (1) CY1107096T1 (es)
DE (1) DE60316454T2 (es)
DK (1) DK1539115T3 (es)
ES (1) ES2293039T3 (es)
HR (1) HRP20050077B1 (es)
IL (1) IL166489A (es)
MX (1) MXPA05001191A (es)
MY (1) MY137049A (es)
NO (1) NO324821B1 (es)
NZ (1) NZ570198A (es)
PE (1) PE20040132A1 (es)
PL (1) PL210119B1 (es)
PT (1) PT1539115E (es)
RU (1) RU2321391C2 (es)
TW (1) TWI363637B (es)
WO (1) WO2004010981A1 (es)
ZA (1) ZA200501641B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
CN101035519A (zh) * 2004-08-04 2007-09-12 阿尔扎公司 以上升的零级释放模式释药的药物缓释组合物及其制备方法
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
WO2006085856A1 (en) * 2005-02-04 2006-08-17 Alza Corporation Methods and dosage forms for reducing side effects of benzisozazole derivatives
JP2009507774A (ja) * 2005-08-04 2009-02-26 アルザ・コーポレーシヨン 改良された性質を提供するポリマー混合物による半透過性膜を含んでなる浸透性用量形態物
US20070166381A1 (en) * 2006-01-06 2007-07-19 Iran Reyes Osmotic dosage form with controlled release and fast release aspects
PT3095447T (pt) 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
US20070232624A1 (en) * 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
SI2037936T1 (sl) 2006-06-21 2014-11-28 Opko Renal, Llc Postopek zdravljenja in prepreäśevanja sekundarnega hiperparatiroidizma
US8524749B2 (en) * 2007-02-09 2013-09-03 Alza Corporation Controlled release compositions of tizanidine
EP3225243B1 (en) * 2007-04-25 2025-09-03 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
SI2481400T1 (sl) 2007-04-25 2014-11-28 Opko IP Holdings II, Inc. Nadzorovano oralno sproščanje sestavkov, ki vsebujejo spojino vitamina D in voskasti nosilec
EP2148684B1 (en) 2007-04-25 2013-01-16 Cytochroma Inc. Method of treating vitamin d insufficiency and deficiency
HRP20110863T1 (hr) * 2007-08-21 2011-12-31 Teva Pharmaceutical Industries Ltd. Oblik produljenog oslobađanja paliperidona
JP2010540465A (ja) 2007-09-25 2010-12-24 テバ ファーマシューティカル インダストリーズ リミティド 安定なイマチニブ組成物
AU2008340101C1 (en) * 2007-12-19 2025-03-06 Janssen Pharmaceutica Nv Dosing regimen associated with long acting injectable paliperidone esters
US20090247553A1 (en) * 2008-03-27 2009-10-01 Actavis Group Ptc Ehf Highly Pure Paliperidone or a Pharmaceutically Acceptable Salt Thereof Substantially Free of Keto Impurity
WO2010009900A1 (en) * 2008-07-25 2010-01-28 Krka, D.D. Novo Mesto Paliperidone composition comprising solid matrix particles
EP2161019A1 (en) 2008-09-05 2010-03-10 KRKA, D.D., Novo Mesto Prolonged release multiparticulate pharmaceutical composition comprising paliperidone
US20110177137A1 (en) 2008-09-15 2011-07-21 Intas Pharmaceuticals Limited Novel dosage form of paliperidone and process for preparing the same
KR101707791B1 (ko) * 2008-09-30 2017-02-17 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 리스페리돈 전달용 이식형 장치
WO2011018246A2 (en) 2009-08-13 2011-02-17 Synthon B.V. Controlled release paliperidone composition
US20110052687A1 (en) * 2009-08-26 2011-03-03 Glenmark Generics Ltd Extended release pharmaceutical composition of paliperidone
AU2010308021A1 (en) * 2009-10-16 2012-05-17 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
WO2011114213A1 (en) 2010-03-15 2011-09-22 Inventia Healthcare Private Limited Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic
LT2552484T (lt) 2010-03-29 2020-04-27 Opko Ireland Global Holdings, Ltd. Būdai ir kompozicijos, skirti paratiroidų lygiams sumažinti
JP5894574B2 (ja) * 2010-04-22 2016-03-30 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US20120201886A1 (en) 2010-07-30 2012-08-09 Micro Labs Limited Coated Extended Release Pharmaceutical Compositions Containing Paliperidone
CN102058517A (zh) * 2010-12-31 2011-05-18 泰州万全医药科技有限公司 一种帕潘立酮缓释剂及其制备方法
US20130034605A1 (en) 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
CN102274164B (zh) * 2011-08-22 2014-07-02 长春健欣生物医药科技开发有限公司 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂
WO2013155505A1 (en) 2012-04-14 2013-10-17 Intra-Cellular Therapies, Inc Organic compounds
WO2014102741A2 (en) * 2012-12-28 2014-07-03 University Of The Witwatersrand, Johannesburg Pharmaceutical dosage form
US9708322B2 (en) 2013-03-15 2017-07-18 Intra-Cellular Therapies, Inc. Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CN103271889B (zh) * 2013-05-23 2015-10-28 沈阳药科大学 帕利哌酮新型递增释放渗透泵制剂及其制备方法
CN103385857A (zh) * 2013-06-29 2013-11-13 北京万全德众医药生物技术有限公司 帕利哌酮的药物组合物
WO2015001488A1 (en) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Extended-release tablets of paliperidone and processes of preparation thereof
KR102373288B1 (ko) 2013-12-03 2022-03-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
JP2017509686A (ja) 2014-04-04 2017-04-06 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
AU2015240526A1 (en) 2014-04-04 2016-11-24 Intra-Cellular Therapies, Inc. Organic compounds
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
US20160000654A1 (en) * 2014-07-07 2016-01-07 Cadila Healthcare Limited Method for determining formulation orientation of asymmetric multi-layered osmotic tablets
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104257622B (zh) * 2014-10-01 2020-02-07 浙江华海药业股份有限公司 一种帕利哌酮控释片及其制备方法
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
GR1008842B (el) 2015-08-06 2016-09-05 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
CN105147629B (zh) * 2015-09-24 2017-08-25 吉林大学 一种异丁利酮片剂及制备方法
MX385678B (es) 2016-01-26 2025-03-18 Intra Cellular Therapies Inc Gamma-carbolinas heterocíclicas fusionadas sustituidas, composiciones farmacéuticas y métodos de uso.
IL297676B2 (en) 2016-03-25 2023-12-01 Intra Cellular Therapies Inc A controlled or delayed release pharmaceutical preparation containing a deuterated compound
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
EP3439638A1 (en) 2016-04-05 2019-02-13 Pharmathen S.A. Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
EP3525763B1 (en) 2016-10-12 2025-03-05 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
WO2018098115A1 (en) * 2016-11-23 2018-05-31 Children's Hospital Medical Center Paliperidone for treatment of drug refractory irritability and autism spectrum disorder
CN106727392A (zh) * 2016-12-15 2017-05-31 上海奕利制药有限公司 一种帕利哌酮缓释片剂及其制备方法
US10961245B2 (en) 2016-12-29 2021-03-30 Intra-Cellular Therapies, Inc. Substituted heterocycle fused gamma-carbolines for treatment of central nervous system disorders
US10906906B2 (en) 2016-12-29 2021-02-02 Intra-Cellular Therapies, Inc. Organic compounds
IL304026B2 (en) 2017-03-24 2024-11-01 Intra Cellular Therapies Inc A pharmaceutical preparation containing 1-(4-fluoro-phenyl)-4-((Sa10,Rb6)-3-D2-2,2-methyl-2, 3, a10, 10, 9, b6- hexahydro-H7, H1- Pyrido[3',4',:4,5]pyrrolo[3,2,1-de]quioxalin-8-yl)-butan-1-one and its uses
JP7223742B2 (ja) 2017-07-26 2023-02-16 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
MX2020000967A (es) 2017-07-26 2020-09-28 Intra Cellular Therapies Inc Compuestos organicos.
JP7462568B2 (ja) 2018-03-23 2024-04-05 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
BR112020019181A2 (pt) 2018-03-23 2021-01-05 Intra-Cellular Therapies, Inc. Compostos orgânicos
EP3801527B1 (en) 2018-06-08 2025-02-19 Intra-Cellular Therapies, Inc. Fused gamma-carbolines for acute treatment of anxiety or depression
WO2020047241A1 (en) 2018-08-29 2020-03-05 Intra-Cellular Therapies, Inc. Novel compositions and methods
BR112021003655A2 (pt) 2018-08-31 2021-05-18 Intra-Cellular Therapies, Inc. métodos novos
CN118873536A (zh) 2018-08-31 2024-11-01 细胞内治疗公司 新方法
BR112022000231A2 (pt) 2019-07-07 2022-02-22 Intra Cellular Therapies Inc Novos métodos
KR102285510B1 (ko) 2019-10-29 2021-08-04 강동국 양액 농도조절용 캡슐 및 그 용도
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
CN113616610B (zh) * 2021-07-30 2023-05-12 石药集团欧意药业有限公司 一种帕利哌酮缓释片及其制备方法
WO2023220251A2 (en) * 2022-05-12 2023-11-16 Celanese Eva Performance Polymers Llc Implantable medical device for the delivery of an antipsychotic
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods
KR20250123225A (ko) 2022-12-30 2025-08-14 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2026011166A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Substituted heterocycles for use in the treatment of diseases involving the 5-ht2a receptor
WO2026011136A1 (en) 2024-07-03 2026-01-08 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4656092A (en) * 1985-10-15 1987-04-07 R. P. Scherer Corporation Target shooting capsules
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
EP0649651B1 (en) * 1993-09-28 2000-12-13 R.P. Scherer GmbH Soft gelatin capsule manufacture
SG47445A1 (en) * 1993-11-19 1998-04-17 Janssen Pharmaceutica Nv Microencapsulated 3-piperidinyl-substituted1 1 2-benzisoxazoles and 1 2-benzisothiazoles
TW487572B (en) * 1996-05-20 2002-05-21 Janssen Pharmaceutica Nv Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters
CN101518517B (zh) * 1996-08-16 2014-11-26 阿尔萨公司 药物剂量逐渐增加的剂型
US6919373B1 (en) * 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
ATE277594T1 (de) * 1998-06-03 2004-10-15 Alza Corp Vorrichtungen um eine verlängerte medikamententherapie zu erreichen
KR20070040421A (ko) * 1998-11-02 2007-04-16 알자 코포레이션 항우울제의 제어된 전달
US6706282B1 (en) * 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
DK1140012T3 (da) * 1998-12-17 2004-07-12 Alza Corp Omdannelse af væskefyldte gelatinekapsler til systemer til kontrolleret frigivelsessystemer ved flere coatinger
EE05022B1 (et) * 1999-03-31 2008-06-16 Janssen Pharmaceutica N.V. Eelthelatineeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis ja hüdrofiilne kontrollitud vabanemisega preparaat
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6375981B1 (en) * 2000-06-01 2002-04-23 A. E. Staley Manufacturing Co. Modified starch as a replacement for gelatin in soft gel films and capsules
US6530962B1 (en) * 2001-08-31 2003-03-11 R.P. Scherer Technologies, Inc. Emulsion of water soluble dyes in a lipophilic carrier

Also Published As

Publication number Publication date
TW200418524A (en) 2004-10-01
BR0313139A (pt) 2005-07-05
PE20040132A1 (es) 2004-03-06
RU2321391C2 (ru) 2008-04-10
ZA200501641B (en) 2005-08-31
ES2293039T3 (es) 2008-03-16
CY1107096T1 (el) 2012-10-24
EP1539115A1 (en) 2005-06-15
MXPA05001191A (es) 2005-09-12
MY137049A (en) 2008-12-31
AU2003256844A1 (en) 2004-02-16
HRP20050077B1 (hr) 2013-11-22
HRP20050077A2 (en) 2005-12-31
US20040092534A1 (en) 2004-05-13
CO5580742A2 (es) 2005-11-30
DK1539115T3 (da) 2008-01-28
IL166489A (en) 2014-01-30
DE60316454D1 (de) 2007-10-31
DE60316454T2 (de) 2008-06-26
ATE373472T1 (de) 2007-10-15
PL210119B1 (pl) 2011-12-30
PT1539115E (pt) 2008-01-14
CA2494234C (en) 2009-10-27
IL166489A0 (en) 2006-01-15
CA2494234A1 (en) 2004-02-05
HK1072559A1 (en) 2005-09-02
RU2005102105A (ru) 2005-08-10
WO2004010981A1 (en) 2004-02-05
CN1684670A (zh) 2005-10-19
PL376258A1 (en) 2005-12-27
TWI363637B (en) 2012-05-11
EP1539115B1 (en) 2007-09-19
JP2005535682A (ja) 2005-11-24
JP4500679B2 (ja) 2010-07-14
KR20050044895A (ko) 2005-05-13
NO324821B1 (no) 2007-12-10
KR100699516B1 (ko) 2007-03-26
NO20050956L (no) 2005-04-27
NZ570198A (en) 2010-01-29

Similar Documents

Publication Publication Date Title
AR040721A1 (es) Metodos y formas de dosificacion para l aliberacion controlada de paliperidona
UY27907A1 (es) Métodos y formas de dosificación para la liberación controlada de paliperidona
UY27789A1 (es) Metodos y modalidades de dosificación para la liberación controlada de oxicodona.
AR031978A1 (es) Formas de dosificacion de liberacion sostenida, el uso de las mismas para la manufactura de un medicamento para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia y una composicion
Cui et al. Efficacy and safety of long‐term tadalafil 5 mg once daily combined with sildenafil 50 mg as needed at the early stage of treatment for patients with erectile dysfunction
DK1001772T3 (da) Forbedret afgivelse af flere doser af et medikament
AR040722A1 (es) Formulaciones y formas de dosificacion para la administracion controlada de topiramato
PT932388E (pt) Forma de dosagem e metodo para administracao de farmacos
DK1173178T3 (da) Præparat, der omfatter apomorfin og sildenafil, og anvendelse deraf til behandling af erektil dysfunktion
PH12021550302A1 (en) Methods for the administration of certain vmat2 inhibitors
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
TW200500098A (en) Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
ECSP066534A (es) Formas de dosificacion de oxicodona de liberacion controlada, orales, una vez al dia
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
IL174562A0 (en) Oros push-stick for controlled delivery of active agent
NO20073403L (no) Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1
ES2563068T3 (es) Tratamiento de esclerosis múltiple (MS) con Campath-1H
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
UY28457A1 (es) Nueva composición
CO5700723A2 (es) Uso de un derivado de amina ciclica especifico o de sus sales farmaceuticamente aceptables para tratar y prevenir la insuficiencia cardiaca
AR055030A1 (es) Metodos y formas de dosificacion para la provision controlada de paliperidona y risperidona
ECSP003661A (es) Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
Fountoulakis et al. Beneficial effect of long-acting injectable risperidone on the neurocognitive deficit of a schizophrenic patient: a case report
GT200000187A (es) Un estuche de combinacion usado en el tratamiento del paludismo.
PH12019501607A1 (en) Tapentadol nasal composition

Legal Events

Date Code Title Description
FB Suspension of granting procedure